Lung Cancer

Months after I was told I was in remission for stage 3B lung cancer, my "normal" shifted as the COVID-19 pandemic arrived.

Some with metastatic cancers receiving end-of-life-initiated immunotherapy may have a decreased risk of mortality when treated at a high-volume facility, research found.

Rates of early mortality from NSCLC decreased in states with Medicaid expansion, according to recent research.

This past holiday season made me realize that I feel a strong sense of fulfillment as a cancer survivor and caregiver.

2023 brought some disappointing cancer news to me, but 2024, I have faith in you.

The Food and Drug Administration approved Udenyca Onbody, an administration device for Udenyca, a biosimilar of Neulasta.

The Food and Drug Administration stopped enrollment on a clinical trial evaluating LN-145 TIL for non-small cell lung cancer after a patient on the trial died.

The pharmaceutical company submitted applications for the FDA to consider approval of Rybrevant plus lazertinib for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer with EGFR exon 19 deletions or L858 substitution mutations.

The FDA granted priority review of patritumab deruxtecan for the treatment of locally advanced or metastatic EGFR-mutated non-small cell lung cancer previously treated with two or more systemic therapies.

In a recent study, tarlatamab resulted in improved objective responses and improved survival outcomes in patients with small-cell lung cancer.

The Gilotrif-Erbitux treatment combination demonstrated antitumor activity in patients with EGFR exon 20 insertion-positive NSCLC, according to a recent study.

When I received my CURE magazine last week, I was fascinated to see a red sticker on the cover indicating it was the lung cancer special edition.

As ‘Big Bang Theory’ star Kate Micucci announced that she is cancer-free and ‘Married at First Sight’ dating coach Mel Schilling announced her cancer diagnosis, here is what’s happening in the oncology space this week.

As Anna “Chickadee” Cardwell from “Here Comes Honey Boo Boo” dies from cancer and former tennis player Chris Evert announces cancer diagnosis, here is what’s happening in the oncology space this week.

There is hope with cancer! Do not let anyone tell you differently — even a physician.

Here's what you can be thankful for...

The Food and Drug Administration gave the green light to a phase 1/2 trial of KSQ-001EX for patients with melanoma, head and neck squamous cell carcinoma and non-small cell lung cancer.

The recent FDA approval of the next-generation tyrosine kinase inhibitor Augtyro provides patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer another treatment option when the disease becomes resistant to other therapies.

As Shannen Doherty revealed her cancer diagnoses and upcoming podcast and a woman with breast cancer completed her bucket list, here is what’s happening in the oncology space this week.

Treatment with Imfinzi for patients with advanced or metastatic NSCLC and limited physical performance status offered beneficial overall survival and maintained quality of life.

A recent study revealed that patients with recurrent or metastatic non-small cell lung cancer tended to have better overall survival compared with those diagnosed with stage 4 disease.

A recent study found that healthy tissue near the sites of lung tumors may contain genetic information that could serve as a predictor of possible cancer recurrence.

Dr. Nabil Rizk, chief of thoracic surgery at Hackensack University Medical Center, explains that segmentectomy is “just a little bit more of a refined way of treating cancers.”

Diane Messick, a three-time lung cancer survivor, tells CURE® about her cancer journey which has included a segmentectomy, a lobectomy and radiation treatment since receiving her first diagnosis in 2017.

Every individual is unique in their own way.

The Food and Drug Administration approved six new cancer therapies in November 2023.

Datopotamab deruxtecan elicited encouraging responses in patients with heavily pretreated non–small cell lung cancer harboring actionable genomic alterations.

Immune checkpoint inhibitors and stereotactic radiosurgery do not increase the risk of necrosis among patients with NSCLC who have brain metastases, according to research.

New research revealed that genetic information near healthy tissue surrounding lung tumors may have a better change of determining recurrence in patients with lung cancer.

The Food and Drug Administration approved Augtyro for patients with ROS1-positive metastatic non-small cell lung cancer based on a phase 1/2 trial.